advertisement
Abstract #3609 Published in IGR 4-2
Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy
Stewart WC; Stewart JA; Jackson ALActa Ophthalmologica Scandinavica 2002; 80: 277-281
PURPOSE: To examine the influence on maximal exercise performance in young healthy volunteers of timolol 0.5%, brimonidine 0.2% or placebo versus brimonidine 0.2% and timolol 0.5% used concomitantly. METHODS: The subjects in this prospective, double-masked, crossover comparison were dosed 15 minutes prior to treadmill testing. A period of one week was allowed between tests. RESULTS: The 20 subjects who completed the trials (average age 24.5 ± 7.4) had a mean maximum exercise heart rate of 196 ± 12 bpm for placebo, 182 ± 13 bpm for timolol, 187 ± 10 bpm for brimonidine, and 186 ± 11 bpm for timolol/brimonidine concomitant therapy (p < 0.005). During recovery, the placebo group demonstrated a statistically higher systolic blood pressure (minute 6) and pulse (minutes 2 and 4) (p < 0.01). In addition, subjects treated with timolol/brimonidine demonstrated more premature contractions (atrial or ventricular) overall during exercise and recovery (p = 0.01). The brimonidine and concomitant treatment groups showed the greatest number of adverse events per subject, the most common of which were dizziness and fatigue (p = 0.031). CONCLUSION: This study suggests that both timolol and brimonidine, used alone and concomitantly, cause cardiovascular effects consistent with their pharmacology.
Dr. W.C. Stewart, Pharmaceutical Research Corporation, 1639 Tatum Street, Charleston, SC 29412-2464, USA. pr_admn@bellsouth.net
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
